Masum Hossain

hossain 210x210






President, International Developed Markets, Pfizer


Masum is Regional President IDM, Pfizer Oncology. In this role, he is responsible for Pfizer’s industry-leading portfolio of cancer medicines and biosimilars in the International Developed Markets (IDM) region, which comprises more than 50 countries in Europe as well as Korea, Japan, Australia and New Zealand. In 2020, the 24 medicines in Pfizer's oncology portfolio reached more than 716,000 people living with cancer worldwide.

Masum has 25 years of combined clinical, regulatory and healthcare industry experience. Throughout his career in the industry, he has held numerous leadership positions in a range of therapeutic areas such as cardiovascular, metabolic, rare diseases, oncology and inflammation in emerging and developed markets. He has led several industry initiatives including co-founding and co-chairing the Cancer Drugs Alliance, a multi-stakeholder organization focused on improving access to cancer medicines in Australia. Masum has represented Pfizer on industry bodies and in international speaking and media engagements, discussing key policy issues in Australia and Asia including patient access, disease awareness and national healthcare policy.

Masum is passionate about harnessing the creative power of some of the brightest minds in the pharmaceutical industry to find digital health solutions that make a difference in people’s lives. He believes that open collaboration and a strong culture will help the healthcare industry bring their very best to what they do: serve patients.

A medical graduate from the University of New South Wales, Australia and completing postgraduate studies in clinical epidemiology, Masum began his career in neurosurgery and worked as medical officer with the Australian regulatory agency, the Therapeutic Goods Administration, before moving into the pharmaceutical industry.

Masum holds a Master of Management from Macquarie Graduate School of Management and is a member of the not-for-profit Australian Institute of Company Directors.


Updated: September 2021